Alkermes

Hybrid

Some members of the team work remotely, while others are co-located in one or more offices.

👥501-1,000

📍Mission Viejo

Alkermes

About Alkermes

Alkermes plc is a pharmaceutical manufacturing and biopharmaceutical company developing innovative medicines to help patients with serious chronic conditions.

Alkermes news and updates

KBC Belgium invests into Alkermes, Inc.

Kbc Nv has invested 0.04% in Alkermes plc (NASDAQ:ALKS).

Jan 1, 2019 | whatsonthorold.com

Domain Therapeutics partnered with Alkermes, Inc. on Dec 14th 16'.

Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G protein-coupled receptors (GPCRs), announces today the signing of a licensing agreement for its GPCR bioSensAll™ technology with Alkermes, a biopharmaceutical company that focuses on developing medicines for the treatment of central nervous system diseases.

Jan 1, 2016 | domaintherapeutics.ca

Scimaxglobal signs new client Alkermes, Inc.

To achieve this goal for themselves and their customers, Alkermes selected SciMax Global (SciMax), a global life sciences technology provider, to adapt and implement its proprietary MedInquirer Self-Service Portal.

Jan 1, 2021 | scimaxglobal.com

Alkermes, Inc. launched series of actions on May 26th 22'.

Alkermes plc (Nasdaq: ALKS ) today announced a series of actions as part of its ongoing commitment to strong corporate governance and regular board refreshment.

Jan 1, 2022 | prnewswire.com